122 related articles for article (PubMed ID: 38379194)
21. SHP2 overexpression enhances the invasion and metastasis of ovarian cancer in vitro and in vivo.
Hu Z; Li J; Gao Q; Wei S; Yang B
Onco Targets Ther; 2017; 10():3881-3891. PubMed ID: 28814887
[TBL] [Abstract][Full Text] [Related]
22. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.
Agazie YM; Movilla N; Ischenko I; Hayman MJ
Oncogene; 2003 Oct; 22(44):6909-18. PubMed ID: 14534538
[TBL] [Abstract][Full Text] [Related]
23. Strategies to overcome drug resistance using SHP2 inhibitors.
Liu M; Gao S; Elhassan RM; Hou X; Fang H
Acta Pharm Sin B; 2021 Dec; 11(12):3908-3924. PubMed ID: 35024315
[TBL] [Abstract][Full Text] [Related]
24. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
[TBL] [Abstract][Full Text] [Related]
25. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
Song P; Song B; Liu J; Wang X; Nan X; Wang J
Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
[TBL] [Abstract][Full Text] [Related]
26. Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
Sun B; Jensen NR; Chung D; Yang M; LaRue AC; Cheung HW; Wang Q
Am J Cancer Res; 2019; 9(1):145-159. PubMed ID: 30755818
[TBL] [Abstract][Full Text] [Related]
27. SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma.
Zhou P; Xiao M; Li W; Sun X; Bai Y; Meng F; Zhu Z; Yuan W; Sun K
Front Pharmacol; 2022; 13():841308. PubMed ID: 35462913
[TBL] [Abstract][Full Text] [Related]
28. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
[TBL] [Abstract][Full Text] [Related]
29. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
Lu X; Yu R; Li Z; Yang M; Dai J; Liu M
Cancer Lett; 2024 Feb; 582():216517. PubMed ID: 38101609
[TBL] [Abstract][Full Text] [Related]
30. A ERK/RSK-mediated negative feedback loop regulates M-CSF-evoked PI3K/AKT activation in macrophages.
Wang L; Iorio C; Yan K; Yang H; Takeshita S; Kang S; Neel BG; Yang W
FASEB J; 2018 Feb; 32(2):875-887. PubMed ID: 29046360
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
Cai Z; Hao XY; Liu FX
Arch Oral Biol; 2018 May; 89():20-25. PubMed ID: 29407635
[TBL] [Abstract][Full Text] [Related]
32. Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches.
Tojjari A; Saeed A; Sadeghipour A; Kurzrock R; Cavalcante L
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001644
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine phosphatase SHP2 in ovarian granulosa cells balances follicular development by inhibiting PI3K/AKT signaling.
Wei X; Zheng L; Tian Y; Wang H; Su Y; Feng G; Wang C; Lu Z
J Mol Cell Biol; 2022 Sep; 14(7):. PubMed ID: 36002018
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 1H-pyrazolo[3,4-
Xu WQ; Qi SZ; Zhao JF; Li LP; Ding CH; Liu WS
J Biomol Struct Dyn; 2024 Jan; ():1-9. PubMed ID: 38258435
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma.
Li Y; Yuan Y; Zhang F; Guo A; Cao F; Song M; Fu Y; Xu X; Shen H; Zheng S; Pan Y; Chang W
Front Pharmacol; 2021; 12():739501. PubMed ID: 34790119
[TBL] [Abstract][Full Text] [Related]
36. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
Jiang L; Xu W; Chen Y; Zhang Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
[TBL] [Abstract][Full Text] [Related]
37. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
[TBL] [Abstract][Full Text] [Related]
38. M-CSF secreted by gastric cancer cells exacerbates the progression of gastric cancer by increasing the expression of SHP2 in tumor-associated macrophages.
Zhang S; Ren D; Hou H; Yao L; Yuan H
Aging (Albany NY); 2023 Dec; 15(24):15525-15534. PubMed ID: 38159254
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects.
Lade DM; Nicoletti R; Mersch J; Agazie YM
Eur J Med Chem; 2023 Feb; 247():115017. PubMed ID: 36584630
[TBL] [Abstract][Full Text] [Related]
40. Structure-based discovery of a specific SHP2 inhibitor with enhanced blood-brain barrier penetration from PubChem database.
Ma Y; Li WY; Sun T; Zhang L; Lu XH; Yang B; Wang RL
Bioorg Chem; 2022 Apr; 121():105648. PubMed ID: 35180489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
